What is killing people with hepatitis C virus infection?

Seminars in Liver Disease

Volumn 31, Issue 4, 2011, Pages 331-339

  Grebely, Jason ^a   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

assessment; barriers; care; Hepatitis C virus; treatment

Indexed keywords

ANTIRETROVIRUS AGENT; DIAMORPHINE; OPIATE; PEGINTERFERON; RIBAVIRIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; BLOOD TRANSFUSION; CANNABIS SMOKING; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG OVERDOSE; DRUG TOLERABILITY; DRUG UPTAKE; DRUG USE; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LIFESPAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MIXED INFECTION; MORBIDITY; MORTALITY; OBESITY; PATIENT ASSESSMENT; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; SCREENING TEST; SMOKING; SUICIDE; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; COINFECTION; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS; SUICIDE;

EID: 84455182283     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0031-1297922     Document Type: Article

References (89)

1. Thompson A, Patel K, Tillman H, McHutchison J G. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J Hepatol 2009 50 1 184-194
2. Omland L H., Jepsen P, Krarup H et al, DANVIR Cohort Study. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol 2011 9 1 71-78
3. El-Kamary S S., Jhaveri R, Shardell M D. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011 53 2 150-157
4. McDonald S A., Hutchinson S J., Bird S M. et al. The growing contribution of hepatitis C virus infection to liver-related mortality in Scotland. Euro Surveill 2010 15 18 19562
5. Amin J, Law M G., Bartlett M, Kaldor J M., Dore G J. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006 368 9539 938-945 (Pubitemid 44331386)
6. Duberg A S., Törner A, Davidsdóttir L et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat 2008 15 7 538-550 (Pubitemid 351798992)
7. McDonald S A., Hutchinson S J., Bird S M. et al. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Stat Methods Med Res 2009 18 3 271-283
8. Walter S R., Thein H H., Amin J et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol 2011 54 5 879-886
9. Altekruse S F., McGlynn K A., Reichman M E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009 27 9 1485-1491
10. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008 48 1 137-145 (Pubitemid 351980469)
11. Bosetti C, Levi F, Lucchini F, Zatonski W A., Negri E, La Vecchia C. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007 46 5 827-839 (Pubitemid 46529045)
12. Volk M L., Tocco R, Saini S, Lok A S. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009 50 6 1750-1755
13. NCHECR. Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia. Sydney, Australia National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales 2010
14. Werb D, Wood E, Kerr T, Hershfield N, Palmer R W., Remis R S. Treatment costs of hepatitis C infection among injection drug users in Canada, 20062026. Int J Drug Policy 2011 22 1 70-76
15. Lettmeier B, Móhlberger N, Schwarzer R et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008 49 4 528-536
16. NCHECR. HIV, viral hepatitis, and sexually transmissible infections in Australia Annual Surveillance Report. Sydney, Australia National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales 2010
17. Mehta S H., Genberg B L., Astemborski J et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008 33 3 126-133
18. Grebely J, Genoway K, Khara M et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007 18 5 437-443 (Pubitemid 47381422)
19. Grebely J, Bryant J, Hull P et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat 2011 18 4 e104-e116
20. Strathdee S A., Latka M, Campbell J et al, Study to Reduce Intravenous Exposures Project. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005 40 Suppl 5 S304-S312 (Pubitemid 40490216)
21. Grebely J, Dore G J. An expanding role for primary care providers in the treatment of hepatitis C virus infection in the community. Hepatology 2011. In press
22. Micallef J M., Kaldor J M., Dore G J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006 13 1 34-41
23. Seeff L B. Natural history of chronic hepatitis C. Hepatology 2002 36 5, Suppl 1 S35-S46 (Pubitemid 35253462)
24. Aitken C K., Lewis J, Tracy S L. et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008 48 6 1746-1752
25. Mehta S H., Cox A, Hoover D R. et al. Protection against persistence of hepatitis C. Lancet 2002 359 9316 1478-1483 (Pubitemid 34457766)
26. Micallef J M., Macdonald V, Jauncey M et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007 14 6 413-418 (Pubitemid 46744050)
27. Osburn W O., Fisher B E., Dowd K A. et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010 138 1 315-324
28. Page K, Hahn J A., Evans J et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009 200 8 1216-1226
29. Grebely J, Conway B, Raffa J D., Lai C, Krajden M, Tyndall M W. Hepatitis C virus reinfection in injection drug users. Hepatology 2006 44 5 1139-1145 (Pubitemid 44748365)
30. van de Laar T J., Molenkamp R, van den Berg C et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol 2009 51 4 667-674
31. Seeff L B. The history of the natural history of hepatitis C (19682009). Liver Int 2009 29 Suppl 1 89-99
32. Freeman A J., Dore G J., Law M G. et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001 34 4 Pt 1 809-816 (Pubitemid 32928008)
33. Thein H H., Yi Q, Dore G J., Krahn M D. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008 22 15 1979-1991
34. Thein H H., Yi Q, Dore G J., Krahn M D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008 48 2 418-431
35. Kenny-Walsh E, Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999 340 16 1228-1233 (Pubitemid 29181642)
36. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000 32 1 91-96 (Pubitemid 30432371)
37. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997 349 9055 825-832 (Pubitemid 27129209)
38. Wiley T E., Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002 97 3 700-706 (Pubitemid 34245901)
39. Sterling R K., Stravitz R T., Luketic V A. et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004 2 6 469-473 (Pubitemid 38698361)
40. Vogt M, Lang T, Frösner G et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999 341 12 866-870 (Pubitemid 29427048)
41. Casiraghi M A., De Paschale M, Romanó L et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 2004 39 1 90-96 (Pubitemid 38461471)
42. Minola E, Prati D, Suter F et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002 99 12 4588-4591 (Pubitemid 34627231)
43. Ostapowicz G, Watson K J., Locarnini S A., Desmond P V. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998 27 6 1730-1735 (Pubitemid 28264702)
44. Harris D R., Gonin R, Alter H J. et al, National Heart, Lung, and Blood Institute Study Group. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001 134 2 120-124 (Pubitemid 32096339)
45. Hutchinson S J., Bird S M., Goldberg D J. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 2005 3 11 1150-1159 (Pubitemid 41565383)
46. Graham C S., Baden L R., Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001 33 4 562-569 (Pubitemid 32709592)
47. Ragni M V., Belle S H. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001 183 7 1112-1115 (Pubitemid 32230961)
48. Thomas D L., Shih J W., Alter H J. et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996 174 4 690-695 (Pubitemid 26325882)
49. Grebely J, Raffa J D., Lai C et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat 2011 18 1 32-41
50. Pontisso P, Gerotto M, Benvegnó L, Chemello L, Alberti A. Coinfection by hepatitis B virus and hepatitis C virus. Antivir Ther 1998 3 Suppl 3 137-142 (Pubitemid 28528329)
51. Gaeta G B., Stornaiuolo G, Precone D F. et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 2003 39 6 1036-1041 (Pubitemid 37523777)
52. Monto A, Alonzo J, Watson J J., Grunfeld C, Wright T L. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002 36 3 729-736 (Pubitemid 34977185)
53. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T, LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003 39 6 1049-1055 (Pubitemid 37523779)
54. Hourigan L F., Macdonald G A., Purdie D et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999 29 4 1215-1219 (Pubitemid 29168757)
55. Ortiz V, Berenguer M, Rayón J M., Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002 97 9 2408-2414
56. Leandro G, Mangia A, Hui J et al, HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006 130 6 1636-1642
57. Adinolfi L E., Gambardella M, Andreana A, Tripodi M F., Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001 33 6 1358-1364 (Pubitemid 32496971)
58. Singal A G., Volk M L., Jensen D, Di Bisceglie A M., Schoenfeld P S. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010 8 3 280-288, 288, e1
59. Hézode C, Roudot-Thoraval F, Nguyen S et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005 42 1 63-71 (Pubitemid 40911312)
60. Hsu P C., Federico C A., Krajden M et al. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol 2011 Epub ahead of print
61. Nelson P K., Mathers B M., Cowie B et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011 378 9791 571-583
62. Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect 2006 82 Suppl 3 iii56-iii63 (Pubitemid 43901613)
63. Degenhardt L, Bucello C, Mathers B et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011 106 1 32-51
64. Gibson A, Degenhardt L, Mattick R P., Ali R, White J, O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 2008 103 3 462-468 (Pubitemid 351208102)
65. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009 105 1-2 9-15
66. Gibson A, Randall D, Degenhardt L. The increasing mortality burden of liver disease among opioid-dependent people: cohort study. Addiction 2011 106 12 2186-2192
67. Darke S, Kaye S, Duflou J. Comparative cardiac pathology among deaths due to cocaine toxicity, opioid toxicity and non-drug-related causes. Addiction 2006 101 12 1771-1777 (Pubitemid 44899699)
68. Harris H E., Ramsay M E., Andrews N J., HCV National Register Steering Group. Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure. Epidemiol Infect 2006 134 3 472-477
69. Iloeje U H., Yang H I., Jen C L. et al, Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus Study Group. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007 5 8 921-931 (Pubitemid 47161142)
70. Yang H I., Chen C J., Jen C L. et al. Causes of death associated with hepatitis B or hepatitis C virus infections in a long-term population-based cohort study. Paper presented at: Digestive Disease Week 2007; May 1924, 2007; Washington, DC
71. Thomas D L., Leoutsakas D, Zabransky T, Kumar M S. Hepatitis C in HIV-infected individuals: cure and control, right now. J Int AIDS Soc 2011 14 22
72. Thomas D L., Astemborski J, Rai R M. et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000 284 4 450-456 (Pubitemid 30484478)
73. Thomas D L., Astemborski J, Vlahov D et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 2000 181 3 844-851 (Pubitemid 30194464)
74. Goedert J J., Eyster M E., Lederman M M. et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002 100 5 1584-1589 (Pubitemid 34925132)
75. Torriani F J., Rodriguez-Torres M, Rockstroh J K. et al, APRICOT Study Group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004 351 5 438-450 (Pubitemid 38988593)
76. Hadziyannis S J., Sette H Jr, Morgan T R. et al, PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 5 346-355
77. Volberding P A., Deeks S G. Antiretroviral therapy and management of HIV infection. Lancet 2010 376 9734 49-62
78. Weber R, Sabin C A., Friis-Móller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006 166 15 1632-1641 (Pubitemid 44232373)
79. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001 32 3 492-497 (Pubitemid 32173638)
80. Lohse N, Hansen A B., Pedersen G et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007 146 2 87-95 (Pubitemid 351640011)
81. Gane E J., Roberts S K., Stedman C A. et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010 376 9751 1467-1475
82. Chak E, Talal A H., Sherman K E., Schiff E R., Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011 Epub ahead of print
83. Australian Government Department of Health and Ageing. Hepatitis C Subcommittee of the Ministerial Advisory Committee on AIDS SHH, the Blood Borne Virus and Sexually Transmissible Infections Subcommittee of the Australian Population Health Development Committee. National hepatitis C testing policy. Canberra Australian Government Department of Health and Ageing 2007
84. Treloar C, Newland J, Harris M, Deacon R, Maher L. A diagnosis of hepatitis C - insights from a study on patients' experiences. Aust Fam Physician 2010 39 8 589-592
85. Vergniol J, Foucher J, Terrebonne E et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011 140 7 1970-1979, 1979, e1e3
86. Grebely J, Bryant J, Hull P et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat 2011 18 4 e104-e116
87. Arora S, Thornton K, Murata G et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011 364 23 2199-2207
88. Shepard C W., Finelli L, Alter M J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005 5 9 558-567 (Pubitemid 41196755)
89. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009 49 4 561-573